AU2002234640B8
(en)
*
|
2001-02-24 |
2009-11-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivative, production and use thereof as a medicament
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
CN1894234A
(zh)
*
|
2003-03-25 |
2007-01-10 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
JP4806628B2
(ja)
|
2003-05-05 |
2011-11-02 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤
|
JP2007511467A
(ja)
|
2003-05-14 |
2007-05-10 |
タケダ サン ディエゴ インコーポレイテッド |
ジペプチジルペプチダーゼインヒビター
|
BRPI0411713B8
(pt)
*
|
2003-06-20 |
2021-05-25 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
|
KR100744893B1
(ko)
*
|
2003-06-20 |
2007-08-01 |
에프. 호프만-라 로슈 아게 |
Dpp-iv 저해제로서 헥사하이드로피리도아이소퀴놀린
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7723344B2
(en)
*
|
2003-08-13 |
2010-05-25 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1699777B1
(en)
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US20050065144A1
(en)
*
|
2003-09-08 |
2005-03-24 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
US20050137142A1
(en)
|
2003-11-03 |
2005-06-23 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
AU2005210004B2
(en)
|
2004-02-05 |
2010-10-28 |
Probiodrug Ag |
Novel inhibitors of glutaminyl cyclase
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN102134230B
(zh)
|
2004-03-15 |
2019-06-28 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
US7687638B2
(en)
|
2004-06-04 |
2010-03-30 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
KR100917545B1
(ko)
*
|
2004-11-30 |
2009-09-16 |
에프. 호프만-라 로슈 아게 |
당뇨병 치료를 위한 dpp-ⅳ 억제제로서의 치환된벤조퀴놀리진
|
KR100904829B1
(ko)
*
|
2004-12-20 |
2009-06-25 |
에프. 호프만-라 로슈 아게 |
4-아미노피페리딘 유도체
|
EP1828192B1
(en)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
BRPI0607680A2
(pt)
|
2005-04-26 |
2009-09-22 |
Mitsubishi Tanabe Pharma Corp |
agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
BRPI0614732A2
(pt)
*
|
2005-08-11 |
2011-04-12 |
Hoffmann La Roche |
composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados
|
SI1942898T2
(sl)
|
2005-09-14 |
2014-08-29 |
Takeda Pharmaceutical Company Limited |
Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa
|
CN102935081B
(zh)
*
|
2005-09-14 |
2015-03-04 |
武田药品工业株式会社 |
用于治疗糖尿病的二肽基肽酶抑制剂
|
CN102675221A
(zh)
|
2005-09-16 |
2012-09-19 |
武田药品工业株式会社 |
用于制备嘧啶二酮衍生物的方法中的中间体
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
US20100029941A1
(en)
*
|
2006-03-28 |
2010-02-04 |
Takeda Pharmaceutical Company Limited |
Preparation of (r)-3-aminopiperidine dihydrochloride
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
DK1971862T3
(da)
|
2006-04-11 |
2011-02-14 |
Arena Pharm Inc |
Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
BRPI0709984A2
(pt)
|
2006-04-12 |
2011-08-02 |
Probiodrug Ag |
inibidores de enzima
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
JP5323684B2
(ja)
|
2006-05-04 |
2013-10-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
多形体
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
EP2019679B1
(en)
|
2006-05-23 |
2018-06-20 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
JP5236649B2
(ja)
*
|
2006-09-15 |
2013-07-17 |
エフ.ホフマン−ラ ロシュ アーゲー |
エナミンの触媒的不斉水素化によるピリド[2,1−a]イソキノリン誘導体の調製方法
|
ES2371369T3
(es)
*
|
2006-09-15 |
2011-12-30 |
F. Hoffmann-La Roche Ag |
Procedimiento para la preparación de derivados pirido[2,1-a]isoquinolina, que comprende la resolución óptica de una enamina.
|
EP2089383B1
(en)
|
2006-11-09 |
2015-09-16 |
Probiodrug AG |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
US9126987B2
(en)
|
2006-11-30 |
2015-09-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US9656991B2
(en)
|
2007-04-18 |
2017-05-23 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
JP5769966B2
(ja)
*
|
2007-08-17 |
2015-08-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Fab関連疾患治療用プリン誘導体
|
UA99924C2
(xx)
|
2007-08-23 |
2012-10-25 |
Теракос, Инк. |
Похідні бензилбензолу та їх застосування$производные бензилбензола и их применение
|
US20090163718A1
(en)
*
|
2007-12-19 |
2009-06-25 |
Stefan Abrecht |
PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2108960A1
(en)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
WO2010009243A1
(en)
|
2008-07-15 |
2010-01-21 |
Theracos, Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
EP2326326B1
(en)
*
|
2008-08-15 |
2019-10-09 |
Boehringer Ingelheim International GmbH |
Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
|
CN102149407A
(zh)
|
2008-09-10 |
2011-08-10 |
贝林格尔.英格海姆国际有限公司 |
治疗糖尿病和相关病症的组合疗法
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
CN107011345A
(zh)
|
2008-12-23 |
2017-08-04 |
勃林格殷格翰国际有限公司 |
有机化合物的盐形式
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
PL2475428T3
(pl)
|
2009-09-11 |
2015-12-31 |
Probiodrug Ag |
Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
|
EP2504002B1
(en)
|
2009-11-27 |
2019-10-09 |
Boehringer Ingelheim International GmbH |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
CA2786314A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US9181233B2
(en)
|
2010-03-03 |
2015-11-10 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
DK2545047T3
(da)
|
2010-03-10 |
2014-07-28 |
Probiodrug Ag |
Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
|
EP2556056A1
(en)
|
2010-04-06 |
2013-02-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
MX341025B
(es)
|
2010-05-05 |
2016-08-04 |
Boehringer Ingelheim Int Gmbh * |
Terapia de combinacion.
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
NZ603319A
(en)
|
2010-06-24 |
2015-04-24 |
Boehringer Ingelheim Int |
Diabetes therapy
|
WO2012018950A1
(en)
|
2010-08-03 |
2012-02-09 |
Beth Israel Deaconess Medical Center |
Methods and compositions for treatment of metabolic disorders
|
WO2012040279A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
PE20140859A1
(es)
|
2011-02-25 |
2014-07-25 |
Merck Sharp & Dohme |
Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
|
EP2686313B1
(en)
|
2011-03-16 |
2016-02-03 |
Probiodrug AG |
Benzimidazole derivatives as inhibitors of glutaminyl cyclase
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
PL2731947T3
(pl)
|
2011-07-15 |
2019-07-31 |
Boehringer Ingelheim International Gmbh |
Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US20130303462A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
BR112015002080A2
(pt)
|
2012-08-02 |
2017-07-04 |
Merck Sharp & Dohme |
composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
EP2958562A4
(en)
|
2013-02-22 |
2016-08-10 |
Merck Sharp & Dohme |
BICYCLIC ANTIDIABETIC COMPOUNDS
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
JP2018507914A
(ja)
|
2015-03-09 |
2018-03-22 |
インテクリン・セラピューティクス・インコーポレイテッド |
非アルコール性脂肪肝疾患および/またはリポジストロフィーの処置のための方法
|
WO2017017042A1
(en)
*
|
2015-07-27 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
CN105412096A
(zh)
*
|
2015-12-15 |
2016-03-23 |
上海壹志医药科技有限公司 |
药根碱的药物用途
|
EP4233840A3
(en)
|
2016-06-10 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|
EP3551176A4
(en)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC HETEROCYCLIC COMPOUNDS
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
BR112019020485A2
(pt)
|
2017-04-03 |
2020-05-12 |
Coherus Biosciences, Inc. |
Agonista ppary para tratamento de paralisia supranuclear progressiva
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|